Contineum Therapeutics, Inc. - 8-K Filing
Contineum reported Q2 net loss of $15.2M and cash balance of $236.6M as it advances clinical trials for IPF, MDD, and chronic pain. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $CTNM